Graphic representation of a dark, textured DGL licorice tablet with white energetic lines on a bright green background, symbolizing the soothing properties of the supplement for digestive health.

Top view of numerous uniform DGL licorice tablets neatly arranged, showcasing the speckled texture of the supplements known for supporting digestive health.

Deglycyrrhizinated licorice

£6.20

Product variants

Boosts digestive enzymes
Improves nutrient absorption
Helps with gut healing and optimal gut health

Quantity

28 day supply (£0.22 / day)

ADD TO YOUR PERSONALISED STACK. BILLED AND DELIVERED EVERY 4 WEEKS.

Tax included. Shipping calculated at checkout.

Vegan

Vegetarian

Non-GMO

Gluten Free

No fillers

The basics

DGL (deglycyrrhizinated licorice) taps into the age-old benefits of licorice root, but without the glycyrrhizin that can cause certain side effects. This form does not affect people with blood pressure issues.

This modified form of licorice has been gaining popularity, particularly in the holistic health arena, for its potential role in aiding digestive health and bolstering the gut's natural healing processes.

The need to know

What are the benefits?

Boosts digestive enzymes
Improves nutrient absorption
Helps with gut healing and optimal gut health

The Science

At the heart of DGL's efficacy is its capability to stimulate the production of digestive enzymes. Enzymes are proteinaceous molecules that act as catalysts, speeding up chemical reactions. In the digestive context, these enzymes break down food into their elementary forms—carbohydrates into simple sugars, proteins into amino acids, and fats into fatty acids and glycerol. With enhanced enzyme activity, food gets processed more efficiently, leading to fewer digestive complications.

Furthermore, licorice root, from which DGL is derived, has a storied history in traditional medicine for its gut-healing properties. Compounds in DGL bolster the mucous membrane lining of the stomach and intestines. This mucosal layer acts as a protective barrier against stomach acids and pathogens. By reinforcing this barrier, DGL helps in curbing issues like ulcers and acid reflux. This makes it effective for use in gut healing in conditions like SIBO.

How will I know its working?

You may experience a decrease in digestive discomforts such as bloating or acid reflux. There could be an improvement in bowel regularity and consistency. A general sensation of feeling lighter post-meals, and possibly a reduction in any chronic gut-associated pain or inflammation, can be indicators of DGL's benefits kicking in.

When to take it?

Chew 1-2 tablets daily with food and water, unless specified otherwise on the sachet.

Ingredients

Active Ingredients	Amount Per Serving	% Daily Value
Deglycyrrhizinated Licorice (DGL) Root Extract	385mg
Glycine	50mg
Other ingredients: Erythritol, Xylitol, Stearic Acid, Hydroxypropyl Methyl-Cellulose, Calcium Palmitate, Maltodextrin, Silica, Rebaudioside A, Oil Of Peppermint

Did you know?

Publications you might find interesting

Want to go a bit deeper?

The latest research

1. Asl, M.N., and Hosseinzadeh, H. ""Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds."" Phytotherapy Research 22.6 (2008): 709-724.

2. Thiyagarajan, P., et al. ""Modulation of lipopolysaccharide-induced pro-inflammatory mediators by an extract of Glycyrrhiza glabra and its phytoconstituents."" Inflammopharmacology 18.5 (2010): 211-217.

3. Isbrucker, R.A., and Burdock, G.A. ""Risk and safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin."" Regulatory Toxicology and Pharmacology 46.3 (2006): 167-192.

4. Rees, W.D., et al. ""Treatment of gastric ulceration and dyspepsia with a liquorice compound."" New Zealand Medical Journal 96.737 (1983): 716-718.

5. van Rossum, T.G., et al. ""Pharmacokinetics of intravenous glycyrrhizin after single and multiple doses in patients with chronic hepatitis C infection."" Clinical Therapeutics 21.12 (1999): 2080-2090.